Hutchin Hill Capital’s iRadimed IRMD Stock Holding History

Hutchin Hill Capital’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-27,400	Closed	-$525K	–	624
2016 Q1	$525K	Buy	+27,400	New	+$524K	0.02%	516

Other funds holding IRMD

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

McKinley Capital Management Anchorage, Alaska $571M AUM 36.44% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hutchin Hill Capital's IRMD Position: Q2 2016 in Review

Hutchin Hill Capital sold out of iRadimed (IRMD) in Q2 2016, closing a stake of 27,400 shares — an estimated $525K sold.

Hutchin Hill Capital first reported a position in IRMD in Q1 2016 and held it in 1 quarter. The position peaked at $525K in Q1 2016. 60 funds tracked by Wall St. Rank hold IRMD as of Q2 2016.

Hutchin Hill Capital reported no remaining iRadimed position as of Q2 2016 after selling out during the quarter.
Hutchin Hill Capital sold 27,400 iRadimed shares in Q2 2016, an estimated $525K.
Hutchin Hill Capital first reported a position in iRadimed in Q1 2016 and held it in 1 quarter.
Hutchin Hill Capital's iRadimed position peaked at $525K in Q1 2016.
60 funds tracked by Wall St. Rank held iRadimed as of Q2 2016.

Based on Hutchin Hill Capital's 13F filing for Q2 2016, filed 15 Aug 2016.